申请人:Merck, Sharp & Dohme Corp.
公开号:US07947714B2
公开(公告)日:2011-05-24
The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
本发明涉及抑制甘氨酸转运蛋白GlyT1的哌啶化合物,该化合物在治疗与甘氨酸能或谷氨酸能神经递质功能障碍和与甘氨酸转运蛋白GlyT1有关的神经系统和精神障碍及疾病方面具有用途。